Skip to main content
SpringerLink
Log in

Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular remodeling in patients with heart failure, especially heart failure with reduced ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme inhibitors (ACEI). Acute myocardial infarction (AMI) complicated by mitral regurgitation exacerbates ventricular remodeling and increases the risk of heart failure. There is limited evidence on the effects of early administration of ARNI in patients with AMI complicated by mitral regurgitation. The aim of this trial was to examine the effectiveness and the safety of early administration of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation. This was a randomized, single-blind, parallel-group, controlled trial. From June 2021 to June 2022, we enrolled 142 consecutive patients with AMI complicated by moderate-to-severe mitral regurgitation and followed them for 12 months. The patients received standard treatment for AMI and were randomly assigned to receive ARNI or benazepril. The primary efficacy end points were the differences in mitral regurgitant jet area (MRJA), mitral regurgitant volume (MRV), concentration of n-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume and end-systolic volume (LVEDV and LVESV) between groups and within groups at baseline, 1, 3, 6, and 12 months. Secondary end points included the rates of heart failure hospitalization, all-cause mortality, refractory angina, malignant arrhythmias, recurrent myocardial infarction, and stroke. Safety end points included the rates of hyperkalemia, renal dysfunction, hypotension, angioedema, and cough. The ARNI group had significantly lower NT-proBNP levels than the benazepril group at 1 month and later (P < 0.001). MRJA and MRV significantly improved in the ARNI group compared with the benazepril group at 12 months (MRJA: − 3.21 ± 2.18 cm2 vs. − 1.83 ± 2.81 cm2, P < 0.05; MRV: − 27.22 ± 15.22 mL vs. − 13.67 ± 21.02 mL, P < 0.001). The ARNI group also showed significant reductions in LVEDV and LVESV (P < 0.05) and improvement in LVEF (P < 0.05). Secondary end point analysis showed a significantly higher rate of heart failure hospitalization in the benazepril group compared with the ARNI group (HR = 2.03, 95% CI 1.12–3.68, P = 0.021). Safety end point analysis showed a higher rate of hypotension in the ARNI group (P < 0.05). Early use of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation can significantly reduce mitral regurgitation, improve ventricular remodeling, and decrease heart failure hospitalization. Nevertheless, caution is needed to avoid hypotension. Chinese Clinical Trial Registry (ChiCTR2100054255) registered on December 11, 2021.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

All relevant data are within the paper.

References

  1. Sharma H, Radhakrishnan A, Nightingale P, Brown S, May J, O’Connor K, Shakeel I, Zia N, Doshi SN, Townend JN, Myerson SG, Kirchhof P, Ludman PF, Adnan Nadir M, Steeds RP (2021) Mitral regurgitation following acute myocardial infarction treated by percutaneous coronary intervention-prevalence, risk factors, and predictors of outcome. Am J Cardiol 157:22–32

    Article  PubMed  Google Scholar 

  2. Nishino S, Watanabe N, Kimura T, Enriquez-Sarano M, Nakama T, Furugen M, Koiwaya H, Ashikaga K, Kuriyama N, Shibata Y (2016) The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up. Circ Cardiovasc Imaging 9:e004841

    Article  PubMed  Google Scholar 

  3. Branch of Cardiovascular Physicians, Chinese Medical Doctor Association, China Cardiovascular Health Alliance, The Expert Consensus Working Group on the Prevention and Treatment of Heart Failure After Myocardial Infarction (2020) 2020 expert consensus on the prevention and treatment of heart failure after myocardial infarction. Chinese Circulation Journal 35:1166–1180

    Google Scholar 

  4. van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR Jr, Ajmone Marsan N, Delgado V, Bax JJ (2020) Left ventricular post-infarct remodeling: implications for systolic function improvement and outcomes in the modern era. JACC Heart Fail 8:131–140

    Article  PubMed  Google Scholar 

  5. Abboud A, Januzzi JL (2021) Reverse cardiac remodeling and ARNI therapy. Curr Heart Fail Rep 18:71-83

    Article  PubMed  Google Scholar 

  6. Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139:1354–1365

    Article  CAS  PubMed  Google Scholar 

  7. Januzzi JL, Omar A, Liu Y, Murphy S, Butler J, Felker GM, Piña IL, Ward J, Solomon S, Contreras J (2022) Association between sacubitril/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: the PROVE-HF Study. Circulation 146:1638–1640

    Article  PubMed  PubMed Central  Google Scholar 

  8. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e895–e1032

    PubMed  Google Scholar 

  9. Solomon SD, McMurray J, Anand IS, Ge J, Lam C, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

    Article  CAS  PubMed  Google Scholar 

  10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627–3639

    Article  CAS  PubMed  Google Scholar 

  11. Nishihara Y, Nishimori M, Sawa T, Uemura K, Nagai S, Todo S, Oota E, Odajima S, Takeuchi K, Ichikawa Y, Kintsu M, Yamauchi Y, Shiraki H, Yamashita K, Fukuda T, Hisamatsu E, Shimizu M, Hirata KI, Tanaka H (2024) Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure. Heart Vessels 39:95–104

    Article  PubMed  Google Scholar 

  12. Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, Granger C, Køber L, Maggioni A, Mann DL, McMurray J, Rouleau JL, Solomon SD, Ducrocq G, Berwanger O, De Pasquale CG, Landmesser U, Petrie M, Leng D, van der Meer P, Lefkowitz M, Zhou Y, Braunwald E (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation 146:1749–1757

    Article  CAS  PubMed  Google Scholar 

  13. He HB, Yang XZ, Shi MQ, Zeng XW, Wu LM, Li LD (2008) Comparison of cardioprotective effects of salvianolic acid B and benazepril on large myocardial infarction in rats. Pharmacol Rep 60:369–381

    CAS  PubMed  Google Scholar 

  14. Charan Sahoo K, Arora S, Goyal S, Kishore K, Ray R, Nag TC, Singh Arya D (2009) Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats. J Renin Angiotensin Aldosterone Syst 10:201–209

    Article  PubMed  Google Scholar 

  15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233–270

    Article  PubMed  Google Scholar 

  16. Ishii M, Kaikita K, Sato K, Sueta D, Fujisue K, Arima Y, Oimatsu Y, Mitsuse T, Onoue Y, Araki S, Yamamuro M, Nakamura T, Izumiya Y, Yamamoto E, Kojima S, Kim-Mitsuyama S, Ogawa H, Tsujita K (2017) Cardioprotective effects of LCZ696 (Sacubitril/Valsartan) after experimental acute myocardial infarction. JACC Basic Transl Sci 2(6):655–668

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chang PC, Lin SF, Chu Y, Wo HT, Lee HL, Huang YC, Wen MS, Chou CC (2019) LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model. Cardiovasc Ther 2019:6032631

    Article  PubMed  PubMed Central  Google Scholar 

  18. Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R, Chau VQ, Nestler JA, Devarakonda T, Ghosh S, Das A, Salloum FN (2018) Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol 72(19):2342–2356

    Article  CAS  PubMed  Google Scholar 

  19. Rezq ASM, El Nozahi M (2021) Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction. Am J Cardiol 143:7–13

    Article  CAS  PubMed  Google Scholar 

  20. Docherty KF, Campbell RT, Brooksbank K, Dreisbach JG, Forsyth P, Godeseth RL, Hopkins T, Jackson AM, Lee M, McConnachie A, Roditi G, Squire IB, Stanley B, Welsh P, Jhund PS, Petrie MC, McMurray J (2021) Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation 144:199–209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray J, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E (2021) Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail 23:1040–1048

    Article  CAS  PubMed  Google Scholar 

  22. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray J, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E (2021) Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med 385:1845–1855

    Article  CAS  PubMed  Google Scholar 

  23. Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C (2022) The PARADISE-MI trial: a new opportunity to improve the left ventricular remodelling in reperfused STEMI. ESC Heart Failure 9:3698–3701

    Article  PubMed  PubMed Central  Google Scholar 

  24. Asgar AW, Mack MJ, Stone GW (2015) Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 65:1231–1248

    Article  PubMed  Google Scholar 

  25. Kumar M, Thompson PD, Chen K (2023) New perspective on pathophysiology and management of functional mitral regurgitation. Trends Cardiovasc Med 33:386–392

    Article  CAS  PubMed  Google Scholar 

  26. Piérard LA, Carabello BA (2010) Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment. Eur Heart J 31:2996–3005

    Article  PubMed  Google Scholar 

  27. Peng B, Xia H, Ni A, Wu G, Jiang X (2015) Serum NT-proBNP on admission can predict ST-segment resolution in patients with acute myocardial infarction after primary percutaneous coronary intervention. Herz 40:898–905

    Article  PubMed  Google Scholar 

  28. Dong Y, Xu Y, Ding C, Yu Z, Yu Z, Xia X, Chen Y, Jiang X (2022) Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial. Cardiovasc Diagn Ther 12:42–54

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hubers SA, Brown NJ (2016) Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 133:1115–1124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, Imaizumi S, Iwata A, Yahiro E, Saku K (2016) LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail 18:386–393

    Article  CAS  PubMed  Google Scholar 

  31. Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray J, Shi V, Lefkowitz M, Rouleau J (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol 73:795–806

    Article  CAS  PubMed  Google Scholar 

  32. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    Article  PubMed  Google Scholar 

  33. Maggioni AP (2022) PARADISE-MI: another example why the results of a trial should not be considered as those of a soccer game. G Ital Cardiol (Rome) 23:157–159

    PubMed  Google Scholar 

  34. Liuzzo G, Volpe M (2022) PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. Eur Heart J 43:559–560

    Article  PubMed  Google Scholar 

  35. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Van Veldhuisen DJ, Zannad F, Comin-Colet J, Pfeffer MA, McMurray J, Solomon SD (2020) Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142:1236–1245

    Article  CAS  PubMed  Google Scholar 

  36. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray J (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6:489–498

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by Hebei Medical Science Research Project Plan (No. 20231885). We thank LetPub (www.letpub.com) for linguistic assistance.

Author information

Author notes

  1. Hongtao Yin, Lixiang Ma are co-first authors.

Authors and Affiliations

  1. Tianjin Medical University, Tianjin, 300000, People’s Republic of China

    Hongtao Yin & Jun Zhang

  2. Department of Cardiology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, People’s Republic of China

    Hongtao Yin, Lixiang Ma, Xiuying Tang & Yingjun Zhou

  3. The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, People’s Republic of China

    Yanqing Zhou & Jiaxiu Shi

  4. Department of Critical Care Medicine, People’s Hospital of Yangjiang, Yangjiang, Guangdong, 529500, People’s Republic of China

    Runjun Li

  5. Depatment of Cardiology, Cangzhou Central Hospital, Tianjin Medical University Teaching Hospital, Cangzhou, Hebei, 061000, People’s Republic of China

    Jun Zhang

Authors
  1. Hongtao Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lixiang Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanqing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiuying Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Runjun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yingjun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiaxiu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Zhang.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, H., Ma, L., Zhou, Y. et al. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial. Heart Vessels (2024). https://doi.org/10.1007/s00380-024-02398-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00380-024-02398-2

Keywords

Search

Navigation